Page 11 - Recursion Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The company had attracted much interest due to its heavy use of artificial intelligence, but its latest fundamentals disappointed many.

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]

Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share, which beat estimates for a loss of 44 cents per share, according to Benzinga Pro

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2023 Earnings Call Transcript February 27, 2024 Recursion Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Chris Gibson: Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to […]

Updated Price for S&P 500 E-Mini (CME: ESM22). Charting, Price Performance, News & Related Contracts.